Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial

PURPOSE: Constipation can be a significant problem in critically unwell patients, associated with detrimental outcomes. Opioids are thought to contribute to the mechanism of bowel dysfunction. We tested if methylnaltrexone, a pure peripheral mu-opioid receptor antagonist, could reverse opioid-induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Parind B., Brett, Stephen J., O’Callaghan, David, Anjum, Aisha, Cross, Mary, Warwick, Jane, Gordon, Anthony C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223905/
https://www.ncbi.nlm.nih.gov/pubmed/32016532
http://dx.doi.org/10.1007/s00134-019-05913-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223905/
https://www.ncbi.nlm.nih.gov/pubmed/32016532
http://dx.doi.org/10.1007/s00134-019-05913-6

Ejemplares similares